COMP <GO>
RMD vs JNJ // EV/EBITDA & P/E VALUATION
ResMed Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RMD 6
— JNJ 9
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 67.90% | -8.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 25.50% | -2.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.9x | 18.5x | +1.40 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 2.97% | +1.70 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 34.70% | -2.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 28.50% | -1.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 6.00% | +3.80 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 0.00% | +0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 5.59 | +6.90 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | RMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 60.4 | -18.59 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.08 | -0.15 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 23.0x | +0.60 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $662.49B | -$626.93B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | JNJ REV | RMD GROSS % | JNJ GROSS % | RMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $94.19B | 59.4% | 67.9% | $1.66B | $19.70B |
| FY 2024 | $4.69B | $88.82B | 56.7% | 69.1% | $1.30B | $19.84B |
| FY 2023 | $4.22B | $85.16B | 44.0% | 44.0% | $503.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
JNJ // BETA 1.08